Abstract: Disclosed is a method of treating a non-topical infection selected from the group consisting of ear infections, skin and soft tissue infections, acne, infected wounds, bacteremia, in a useful warm blooded mammal who is in need of such treatment which comprises topical administration of a pharmaceutical formulation containing a transdermally effective amount of an Oxazolidinone.

Abstract: A process that enables the formation of a high damping, soft polymer gel includes reacting a maleimide copolymer with a maleated polyalkylene and an alkyl diamine under substantially dry conditions sufficient to form a polyalkylene-grafted maleimide copolymer product which then is dispersed with an extender sufficient to form the gel. The steps can be carried out sequentially in a high shear mixer without the need for intermediate steps of cooling and grinding the reaction product of one step before proceeding to the next.

Abstract: The present invention provides a compound of the following formula (I): wherein R1 is methyl or 4-aminobutyl, which may be acylated; X is phenyl or substituted phenyl; W is an esterified group removable by hydrogenolysis. Also disclosed is the preparation method and the application of formula (I) compound.

Abstract: This invention provides compounds of formula I: wherein Z is oxygen or sulfur; R1 is hydrogen, —CHN2, R, CH2OR, CH2SR, or —CH2Y; next to R3 represents a single or double bond; Y is an electronegative leaving group; R2 is CO2H, CH2CO2H, or esters, amides or isosteres thereof; R3 is a group capable of fitting into the S2 subsite of a caspase enzyme; R4 is a hydrogen or C1-6 alkyl or R3 and R4 taken together form a ring; Ring A and Ring B are each heterocyclic rings, and R and R5 are as described in the specification. The compounds are effective inhibitors of apoptosis and IL-1? secretion.

Abstract: Compounds of the formula (I) wherein m, n, A, R1, R2, R3, R4, R5 and R6 are as described herein, together with methods for making the compounds and using the compounds for treatment of diseases or conditions mediated by Cathepsin K.

Abstract: A method is described for the preparation of polymorphic forms of water-soluble derivatives of probucol compounds having the following formula where R1, R2, R3, R4, R5, R6, Z and Z? are defined herein.

Abstract: A device comprises at least one organophosphonium transition metal dye or is provided with a filter, comprising at least one organophosphonium transition metal dye, wherein, in a particular embodiment said device is selected from the group consisting of a scanner, a digitizer, a display and a photographic device.

Abstract: Disclosed is an anionic diinitiator prepared using a diisopropenyl benzene compound and an organo lithium compound having primary polymerization sites. The anionic diinitiators are prepared by admixing a diisopropenyl benzene compound with diethyl ether, ethylene, an organo lithium compound, and a solvent under reaction conditions sufficient to prepare a diinitiator having primary lithium alkyl reactive sites. The diinitiators are particularly useful in preparing block copolymers.

Abstract: Presented are compounds represented by the following general formulas (I) and (II), for inhibiting cysteine protease legumain for modulating associated disease states in subjects

Abstract: Optionally alkyl-substituted 1,4-butanediol is prepared from C4-dicarboxylic acids and/or of derivatives thereof by: a) a gas stream of the C4-dicarboxylic acid or the derivative thereof in a first reactor in the gas phase to obtain a product which contains mainly optionally alkyl-substituted ?-butyro-lactone; b) removing succinic anhydride from the product of step a); c) catalytically hydrogenating the product of step b) in a second reactor in the gas phase to obtain optionally alkyl-substituted 1,4-butanediol; d) removing the desired product from intermediates, by-products and any unconverted reactants; and e) optionally recycling unconverted intermediates into one or both hydrogenation stages. The catalysts employed in each of the hydrogenation stages comprise ?95% by weight of CuO, and ?5% by weight of an oxidic support, and the second reactor has a higher pressure than the first reactor.

Abstract: Sustained release oral solid dosage forms of opioid analgesics are provided as multiparticulate systems which are bioavailable and which provide effective blood levels of the opioid analgesic for at least about 24 hours. A unit dose of the opioid analgesic contains a plurality of substrates including the opioid analgesic in sustained release form. The substrates have a diameter from about 0.1 mm to about 3 mm.

Abstract: The invention relates to a novel process for hydroxymethylating noncyclic ?,?-dialkylcarboxylic acid derivatives with formaldehyde using amide bases at temperatures of from ?40° C. up to the boiling point of the solvent or solvent mixture used.

Abstract: The invention provides novel pyrophosphate synthase inhibitors of formula I as well as compositions comprising such inhibitors and methods for their use.

Abstract: A process for producing optically pure R-hydroxyphenoxypropanoic acid or a salt or ester thereof by reaction of hydroquinone or a salt thereof with an S-halopropanoic acid or a salt thereof in the presence of a mild reducing agent.

Abstract: This invention relates to 1,2-di(4-hydroxyaryl)tetrafluoroethanes of the general formula (I) wherein R are each, independently of one another, hydrogen, F, Cl, Br, I, CN, COOR2, C1-C4-alkyl, C1-C4-alkoxy, C1-C4-alkylthio, C1-C4-perfluoroalkyl, C1-C4-perfluoroalkoxy, C1-C4-perfluoroalkylthio, C1-C4-polyfluoroalkyl, C1-C4-polyfluoroalkoxy, or C1-C4-polyfluoroalkylthio, R2 is C1-C4-alkyl, and n is an integer from 0 to 4. This invention further relates to the preparation of such compounds as well as to precursors and intermediates that can be used in their preparation.

Abstract: Describes a method for recovering trans-1,2-dichloroethene from a liquid feed composition comprising both the cis-and trans-isomers of 1,2-dichloroethene and contaminating amounts of other chlorinated hydrocarbons, e.g., lower alkyl chlorinated hydrocarbons, such as C1-C2 chlorinated hydrocarbons. In one of the described methods, the liquid feed composition is introduced into a first distillation column 10 wherein the stereoisomers and chlorinated hydrocarbons more volatile than the stereoisomers are removed as overhead 12 and charged to a second distillation column 20. In column 20, the stereoisomers are separated from the more volatile chlorinated hydrocarbons, and a bottoms fraction 24 comprising the stereoisomers is charged to a reactive distillation column 30 wherein the cis-isomer is isomerized to the trans-isomer in the liquid phase and in the presence of an organic free-radical initiator, e.g., an azonitrile initiator.

Abstract: Silanes containing halogen which is bound to silicon are prepared using microwave energy. Silicon is reacted with mixtures of elements or compounds selected from the group consisting of halogen or halogen and organohalogen compounds or halogen and hydrogen or halogen and halogen hydrogen or organohalogen compounds or organohalogen compounds and hydrogen or organohalogen compounds and halogen hydrogen or halogen hydrogen or fluorosilanes and hydrogen, or fluorosilanes and halogen hydrogen or hydrogen containing chlorosilanes and hydrogen or hydrogen containing chlorosilanes and halogen hydrogen or organohalogensilanes and hydrogen or organohalogensilanes and halogen hydrogen or hydro-carbons and halogen hydro-carbons.

Abstract: Certain chiral monophosphites and their monothio derivatives are suitable as ligands in the asymmetrical transition-metal-catalyzed hydrogenation, hydroborination and hydrocyanation of prochiral olefins, ketones and imines.

Abstract: A silsesquioxane compound mixture having a high proportion of silsesquioxane compounds bearing bulky substituent groups on side chain and having a degree of condensation of substantially 100% is prepared by a first stage wherein a silane feed comprising a trifunctional silane bearing a bulky substituent group on side chain represented by formula (1): wherein Y is an aliphatic or aromatic organic group optionally having a functional group, X1, X2 and X3 are H, halogen, alkoxy or aryloxy is hydrolyzed in the presence of an acid or base catalyst, and a second stage wherein dehydrating condensation is carried out in the presence of a strong base catalyst while removing the water resulting from condensation out of the reaction system.

Abstract: A method for producing high purity terephthalic acid wherein a slurry having an acetic acid solvent and, dispersed therein, crude terephthalic acid crystals which has been prepared by subjecting a p-alkyl benzene to a liquid phase oxidation in a solvent of acetic acid is continuously converted to a water slurry by the mother liquid exchange, and then the resultant water slurry is subjected to a hydrogenation treatment, which comprises introducing the above acetic acid slurry to a tower having a center axis having a plurality of agitating blades at the top thereof, to form a region having a high concentration of terephthalic acid crystals in the tower through the sedimentation of the terephthalic acid crystals, supplying the water for substitution to the bottom of the tower in such a manner to form an upward water flow while generating a revolving flow of the high concentration region by the rotation of the agitation blade, to thereby subject said terephthalic acid crystals and said upward water flow to a coun